Sanofi-Aventis Spin-Off Novexel Gains Indevus’ Antifungal Aminocandin
This article was originally published in The Pink Sheet Daily
Novexel is solely focused on developing anti-infective compounds such as the Phase I compound aminocandin.
You may also be interested in...
Indevus also expects to out-license Valera's early stage pipeline, as well as several of its own products.
Approval for Schering-Plough’s antifungal comes just one month after FDA cleared it for invasive Aspergillus and Candida infections.
Schering-Plough plans to launch posaconazole for patients at high risk within two weeks.